E.N. Bilalov, A.F. Yusupov, Sh.A. Mukhanov
Improving of treatment of non-exudative age-related macular degeneration
Číslo: 1/2017
Periodikum: Medical and Health Science Journal
DOI: 10.15208/mhsj.2017.02
Klíčová slova: Non-exudative age-related macular degeneration, medotilin, choline alfoscerate, electroretinography, color Doppler imaging, central artery of the retina, short posterior ciliary artery, Neexudující degenerace makulární degenerace související s věkem, medotilin, cholinový alfoscerát, elektroretinografie, barevná dopplerovská imaging, centrální tepna sítnice, krátká posteriorní ciliární arterie
Pro získání musíte mít účet v Citace PRO.
Materials: Results of treatment of 68 patients (122 eyes) with non-exudative age-related macular degeneration (AMD). 2 groups were formed: Group 1 (control) - 34 patients (60 eyes) who received standard treatment; and the Group 2 (basic) - 34 patients (62 eyes) who received standard treatment in addition to medotilin.
Methods: Visometry, tonometry, computer perimetry, electroretinography (ERG) and color Doppler imaging (CDI). All studies were carried out before and after 1, 3 and 6 months after treatment.
Results: After treatment in the main group, in the first 3 months 95% of patients (59 eyes) showed a significant improvement of main functions of the eye. By the 6th month, 84% of patients (52 eyes) reported decline down to the original level, and 16% of cases (10 eyes) were stable and exceeded the data before the treatment. When registering macular ERG 1 month after treatment, the study group showed a significant improvement of figures, which remained consistently high also by the 3rd month of observation. By the 6th month of observation, figures declined slightly and came close to the original level. According to CDI, all patients of the main group recorded after treatment an increase in flows in vessels of the eye. Maximum peak increase of hemodynamic parameters were recorded by the 3rd month of observation. By the 6th month, the majority of patients in this group revealed regress of hemodynamic parameters, but at these, exceeded themselves in their capacity as such before treatment.
Conclusion: Medotilin is effective in treatment of non-exudative AMD and improves visual functions, confirmed by electroretinography and hemodynamics.